V
VR Management, LLC
+ HoldingCASI
+4.71%
3M Return
$0.208
-0.154 (-74.06%)At close
Loading chart…
- High
- 0.375
- Open
- 0.340
- VWAP
- 0.26
- Vol
- 9.96M
- Mkt Cap
- 65.67M
- Low
- 0.208
- Amount
- 2.62M
- EV/EBITDA, TTM
- 0.00
CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Company’s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Company’s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market.
AI analysis of CASI Pharmaceuticals Inc (CASI)
sellCASI Pharmaceuticals Inc is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is facing significant challenges, including delisting from Nasdaq, a massive price drop, poor financial performance, and no positive trading signals. The lack of positive catalysts and the transition to OTC markets further increase the risk, making it unsuitable for the given investor profile.
Analyst Ratings (2)
+1827.71% upside
Buy
2 Buy
0 Hold
0 Sell
Current: 0.21
Low
4.00
Average
4.00
High
4.00
HC Wainwright & Co.
Strong Buy
$4
2025-04-09
HC Wainwright & Co.
2025-04-09
Price Target
$4
Strong Buy
HC Wainwright & Co.
Strong Buy
$6
2024-05-15
HC Wainwright & Co.
2024-05-15
Price Target
$6
Strong Buy
HC Wainwright & Co.
Strong Buy
$12
2023-11-15
HC Wainwright & Co.
2023-11-15
Price Target
$12
Strong Buy
HC Wainwright & Co.
Strong Buy
$10
2023-08-14
HC Wainwright & Co.
2023-08-14
Price Target
$10
Strong Buy
HC Wainwright & Co.
Strong Buy
$10
2023-05-22
HC Wainwright & Co.
2023-05-22
Price Target
$10
Strong Buy
Valuation Metrics
The current forward P/E ratio for CASI Pharmaceuticals Inc (CASI) is -0.58, compared to its 5-year average forward P/E of -2.92.
Whales holding CASI
Events Timeline
News
7.002-26NASDAQ.COMCASI Pharmaceuticals to Be Delisted from Nasdaq
- 8.502-26Benzinga
CASI Pharmaceuticals Plans Transition to OTC Markets After Nasdaq Delisting
9.502-25BenzingaU.S. Stocks Rise as TJX Reports Strong Earnings Beat
- 8.502-25stocktwits
CASI Pharmaceuticals Faces Nasdaq Delisting Decision
- 9.502-25Benzinga
U.S. Stocks Rise in Morning Trading, Dow Jones Up Over 200 Points
CASI FAQ — answered by Alphio AI
CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Company’s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Company’s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
CASI Pharmaceuticals Inc is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is facing significant challenges, including delisting from Nasdaq, a massive price drop, poor financial performance, and no positive trading signals. The lack of positive catalysts and the transition to OTC markets further increase the risk, making it unsuitable for the given investor profile.
2 analysts cover CASI: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 4.00.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.